EMA committee probing new side effects from AstraZeneca vaccine

Brussels, May 7 (UNI) The European Medicine Agency (EMA) informed on Friday
that its committee on vaccine safety has asked AstraZeneca to provide additional data regarding its COVID-19 vaccine for an inquiry into cases of a rare autoimmune disorder arising post vaccination.
Guillain-Barre Syndrome is a condition which causes one’s immune system to attack own peripheral nervous system, resulting symptoms such as numbness, pain and difficulty in walking.
“As part of the review of the regular pandemic summary safety reports for Vaxzevria, AstraZeneca’s Covid-19 vaccine, the PRAC [Pharmacovigilance Risk Assessment Committee] is analyzing data provided by the marketing authorization holder on cases of Guillain-Barre syndrome reported following vaccination,” the regulator said.
According to the statement, the disorder was identified during the vaccine’s marketing authorization process as a possible side effect requiring “specific safety monitoring activities.”
“PRAC has requested the marketing authorisation holder to provide further detailed data, including an analysis of all the reported cases in the context of the next pandemic summary safety report,” the statement read.
This is not the first time that the UK vaccine finds itself under scrutiny over side effects. In March, numerous countries suspended its use over blood clotting. While initially the EMA cleared this specific vaccine for use despite the dangerous but “very rare” side effect, in late April it launched a series of inquiries into what causes blood clotting after inoculation with adenoviral vector-based vaccines, such as Vaxzevria.